Currently, since MEK or PI3K inhibitors fail to induce cancer cell death and lead to the selection of compensatory pathways that maintain tumor growth, we believe that celecoxib and metformin in combination can help overcome the resistance caused by crosstalk and feedback between cell pathways. Here, MAP2K7 is linked to neoplasm.